The inflammatory hypothesis of schizophrenia is not new, but recently it has regained interest because more data suggest a role of the immune system in the pathogenesis of schizophrenia. If increased inflammation of the brain contributes to the symptoms of schizophrenia, reduction of the inflammatory status could improve the clinical picture. Lately, several trials have been conducted investigating the potential of anti-inflammatory agents to improve symptoms of schizophrenia. This study provides an update regarding the efficacy of anti-inflammatory agents on schizophrenic symptoms in clinical studies performed so far. Methods: An electronic search was performed using PubMed, Embase, the National Institutes of Health web site http://www.clinicaltrials.gov, Cochrane Schizophrenia Group entries in PsiTri, and the Cochrane Database of Systematic Reviews. Only randomized, double-blind, placebo-controlled studies that investigated clinical outcome were included. Results: Our search yielded 26 double-blind randomized controlled trials that provided information on the efficacy on symptom severity of the following components: aspirin, celecoxib, davunetide, fatty acids such as eicosapentaenoic acids and docosahexaenoic acids, estrogens, minocycline, and N-acetylcysteine (NAC). Of these components, aspirin (mean weighted effect size [ES]: 0.3, n = 270, 95% CI: 0.06-0.537, I2 = 0), estrogens (ES: 0.51, n = 262, 95% CI: 0.043-0.972, I2 = 69%), and NAC (ES: 0.45, n = 140, 95% CI: 0.112-0.779) showed significant effects. Celecoxib, minocycline, davunetide, and fatty acids showed no significant effect. Conclusion: The results of aspirin addition to antipsychotic treatment seem promising, as does the addition of NAC and estrogens. These 3 agents are all very broadly active substances, and it has to be investigated if the beneficial effects on symptom severity are indeed mediated by their anti-inflammatory aspects.
Concerning the relationships between genes, risk factors and immunity in Alzheimer's disease, Autism, Bipolar disorder , multiple sclerosis, Parkinson's disease, schizophrenia and chronic fatigue
Amazon Music
Pages
Links
- ADHD genes and risk factors
- Alzheimer's disease genes and risk factors
- Anorexia Genes and risk factors
- Alzheimer's genes and Herpes simplex
- Autism genes and risk factors
- Bipolar disorder genes and risk factors
- Bornavirus/host interactome
- Borrelia burgdorferi interactome
- Chlamydia pneumoniae interactome
- Helicobacter Pylori host/pathogen interactome
- Herpes simplex host/pathogen interactome
- P.Gingivalis interactome
- T.Gondii: Host/pathogen interactome
- BOOKSTORE
- Childhood Obesity genes and risk factors
- Chronic Fatigue genes and risk factors
- Depression genes and risk factors
- Multiple sclerosis Genes and risk factors
- Parkinson's disease Genes and risk factors
- Pathways in disease (KEGG)
- Schizophrenia Genes and risk factors
- The Microbiome in disease
- Google Scholar
- Cpr/Aed Online Training Certification AHA&ECC Certified
- ACLS Online Certification
Blog Archive
MicrobeWorld
Microbiology Blog: The weblog for microbiologists
pubmed: microbiome disease
- The Gut-Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
- CO-Releasing Polyoxometalates Nanozyme with Gut Mucosal Immunity and Microbiota Homeostasis Remodeling Effects for Restoring Intestinal Barrier Integrity
- Genome sequence of Eubacterium callanderi AM6, isolated from a Parkinson's disease patient
- The immune response modulated by inoculation of commensal bacteria at birth impacts the gut microbiota and prevents Salmonella colonization
- Tas2r105 ameliorates gut inflammation, possibly through influencing the gut microbiota and metabolites
No comments:
Post a Comment